Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 StudyEldad J. Dann, Ora Paltiel, Osnat Bairey et al.|Blood|2014Cited by 4
Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.Eldad J. Dann, Ora Paltiel, Abraham Korenberg et al.|Blood|2010Cited by 4